A photo of Punam Malik.

Director, Cincinnati Comprehensive Sickle Cell Center

Director, Translational Core Laboratory

Marjory J. Johnson Chair, Gene and Cell Therapy

Professor, UC Department of Pediatrics

513-636-1333

513-636-1330

Board Certified

My Biography & Research

Academic Affiliation

Professor, UC Department of Pediatrics

Departments

Cancer and Blood Diseases, Sickle Cell and Hemoglobin Disorders, Experimental Hematology and Cancer Biology, Cancer and Blood Diseases, Hematology

Science Blog

My Locations

My Education

MBBS: University of Delhi, New Delhi, India, 1985.

MD: University of Delhi, New Delhi, India, 1989.

MS: University of Maryland, Baltimore, MD, 1991.

Fellowship: Children's Hospital Los Angeles, University of Southern California, 1995.

My Publications

End points for sickle cell disease clinical trials: Renal and cardiopulmonary, cure, and low-resource settings. Farrell, AT; Panepinto, J; Desai, AA; Kassim, AA; Lebensburger, J; Walters, MC; Bauer, DE; Blaylark, RM; DiMichele, DM; Gladwin, MT; et al. Blood Advances. 2019; 3:4002-4020.

CRISPR-Cas9 fusion to dominant-negative 53BP1 enhances HDR and inhibits NHEJ specifically at Cas9 target sites. Jayavaradhan, R; Pillis, DM; Goodman, M; Zhang, F; Zhang, Y; Andreassen, PR; Malik, P. Nature Communications. 2019; 10.

Role of the coagulation system in the pathogenesis of sickle cell disease. Nasimuzzaman, M; Malik, P. Blood Advances. 2019; 3:3170-3180.

Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia. McGann, PT; Niss, O; Dong, M; Marahatta, A; Howard, TA; Mizuno, T; Lane, A; Kalfa, TA; Malik, P; Quinn, CT; et al. American Journal of Hematology. 2019; 94:871-879.

Abnormal submaximal cardiopulmonary exercise parameters predict impaired peak exercise performance in sickle cell anemia patients. Powell, AW; Alsaied, T; Niss, O; Fleck, RJ; Malik, P; Quinn, CT; Mays, WA; Taylor, MD; Chin, C. Pediatric Blood and Cancer. 2019; 66.

Elimination of the fibrinogen integrin aMb2-binding motif improves renal pathology in mice with sickle cell anemia. Nasimuzzaman, M; Arumugam, PI; Mullins, ES; James, JM; Vanden Heuvel, K; Narciso, MG; Shaw, MA; McGraw, S; Aronow, BJ; Malik, P. Blood Advances. 2019; 3:1519-1532.

Therapeutic strategies for sickle cell disease: towards a multi-agent approach. Telen, MJ; Malik, P; Vercellotti, GM. Nature Reviews Drug Discovery. 2019; 18:139-158.

A Versatile Tool for the Quantification of CRISPR/Cas9-Induced Genome Editing Events in Human Hematopoietic Cell Lines and Hematopoietic Stem/Progenitor Cells. Jayavaradhan, R; Pillis, DM; Malik, P. Journal of Molecular Biology. 2019; 431:102-110.

Diastolic dysfunction is associated with exercise impairment in patients with sickle cell anemia. Alsaied, T; Niss, O; Powell, AW; Fleck, RJ; Cnota, JF; Chin, C; Malik, P; Quinn, CT; Taylor, MD. Pediatric Blood and Cancer. 2018; 65:e27113-e27113.

Angiotensin receptor signaling in sickle cell anemia has a reno-protective effect on urine concentrating ability but results in sickle glomerulopathy. Roy, S; Rai, P; Mpollo, ME M; Chang, K; Rizvi, T; Shanmukhappa, SK; VandenHeuvel, K; Aronow, B; Inagami, T; Cancelas, JA; et al. American Journal of Hematology. 2018; 93:E177-E181.